世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

COVID-19医薬品 - 世界市場シェア・ランキング、全体売上高・需要予測 2024-2030


COVID-19 Medicine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

COVID-19医薬の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に%のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。 COVID-19医薬の北米... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年4月15日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

COVID-19医薬の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に%のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。
COVID-19医薬の北米市場は、2023年に百万米ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに百万米ドルに達すると予測されています。
COVID-19医薬のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに100万ドルに達するでしょう。
COVID-19医薬のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに100万ドルに達するでしょう。
COVID-19医薬の世界主要企業は、Advanz Pharma、Kyung Poong、Mylan、Novartis、Sanofi、Apotex、Bayer、広州白雲山光華医薬、Ipca Laboratoriesなどである。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。

レポートの範囲
本レポートは、COVID-19医薬の世界市場を包括的に紹介することを目的とし、COVID-19医薬の地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。
COVID-19医薬の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量分析および定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、COVID-19 Medicineに関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
アドバンツファーマ
キョン・プーン
マイラン
ノバルティス
サノフィ
アポテックス
バイエル
広州白雲山光華製薬
イプカ・ラボラトリーズ
四川サニーホープ
ザイダス・カディラ
テバ
サンファーマ
ライジング製薬
KPCグループ
ブリストル研究所
上海中西三威
上海製薬
タイプ別セグメント
錠剤
注射剤
用途別セグメント
軽症患者
重症患者
その他
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

各章の概要
第1章:報告書のスコープ、世界の総市場規模を紹介。本章ではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:COVID-19医薬メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる市場セグメントのブルーオーシャン市場を見つけるのに役立つ。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第5章:地域レベルでのCOVID-19医薬品の収益。各地域の市場規模と発展潜在力を定量的に分析し、世界各国の市場発展、将来発展展望、市場空間、市場規模を紹介する。
第6章 COVID-19医薬品の国別売上高各国・地域のタイプ別、用途別のシグメイトデータを提供している。
第7章:主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 COVID-19 Medicine Product Introduction
1.2 Global COVID-19 Medicine Market Size Forecast
1.3 COVID-19 Medicine Market Trends & Drivers
1.3.1 COVID-19 Medicine Industry Trends
1.3.2 COVID-19 Medicine Market Drivers & Opportunity
1.3.3 COVID-19 Medicine Market Challenges
1.3.4 COVID-19 Medicine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global COVID-19 Medicine Players Revenue Ranking (2023)
2.2 Global COVID-19 Medicine Revenue by Company (2019-2024)
2.3 Key Companies COVID-19 Medicine Manufacturing Base Distribution and Headquarters
2.4 Key Companies COVID-19 Medicine Product Offered
2.5 Key Companies Time to Begin Mass Production of COVID-19 Medicine
2.6 COVID-19 Medicine Market Competitive Analysis
2.6.1 COVID-19 Medicine Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by COVID-19 Medicine Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Medicine as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tablet
3.1.2 Injection
3.2 Global COVID-19 Medicine Sales Value by Type
3.2.1 Global COVID-19 Medicine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global COVID-19 Medicine Sales Value, by Type (2019-2030)
3.2.3 Global COVID-19 Medicine Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Patients With Mild Symptoms
4.1.2 Critically Ill
4.1.3 Other
4.2 Global COVID-19 Medicine Sales Value by Application
4.2.1 Global COVID-19 Medicine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global COVID-19 Medicine Sales Value, by Application (2019-2030)
4.2.3 Global COVID-19 Medicine Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global COVID-19 Medicine Sales Value by Region
5.1.1 Global COVID-19 Medicine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global COVID-19 Medicine Sales Value by Region (2019-2024)
5.1.3 Global COVID-19 Medicine Sales Value by Region (2025-2030)
5.1.4 Global COVID-19 Medicine Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America COVID-19 Medicine Sales Value, 2019-2030
5.2.2 North America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe COVID-19 Medicine Sales Value, 2019-2030
5.3.2 Europe COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific COVID-19 Medicine Sales Value, 2019-2030
5.4.2 Asia Pacific COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America COVID-19 Medicine Sales Value, 2019-2030
5.5.2 South America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa COVID-19 Medicine Sales Value, 2019-2030
5.6.2 Middle East & Africa COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions COVID-19 Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions COVID-19 Medicine Sales Value
6.3 United States
6.3.1 United States COVID-19 Medicine Sales Value, 2019-2030
6.3.2 United States COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe COVID-19 Medicine Sales Value, 2019-2030
6.4.2 Europe COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China COVID-19 Medicine Sales Value, 2019-2030
6.5.2 China COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.5.3 China COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan COVID-19 Medicine Sales Value, 2019-2030
6.6.2 Japan COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea COVID-19 Medicine Sales Value, 2019-2030
6.7.2 South Korea COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia COVID-19 Medicine Sales Value, 2019-2030
6.8.2 Southeast Asia COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India COVID-19 Medicine Sales Value, 2019-2030
6.9.2 India COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.9.3 India COVID-19 Medicine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Advanz Pharma
7.1.1 Advanz Pharma Profile
7.1.2 Advanz Pharma Main Business
7.1.3 Advanz Pharma COVID-19 Medicine Products, Services and Solutions
7.1.4 Advanz Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.1.5 Advanz Pharma Recent Developments
7.2 Kyung Poong
7.2.1 Kyung Poong Profile
7.2.2 Kyung Poong Main Business
7.2.3 Kyung Poong COVID-19 Medicine Products, Services and Solutions
7.2.4 Kyung Poong COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.2.5 Kyung Poong Recent Developments
7.3 Mylan
7.3.1 Mylan Profile
7.3.2 Mylan Main Business
7.3.3 Mylan COVID-19 Medicine Products, Services and Solutions
7.3.4 Mylan COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.3.5 Novartis Recent Developments
7.4 Novartis
7.4.1 Novartis Profile
7.4.2 Novartis Main Business
7.4.3 Novartis COVID-19 Medicine Products, Services and Solutions
7.4.4 Novartis COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.4.5 Novartis Recent Developments
7.5 Sanofi
7.5.1 Sanofi Profile
7.5.2 Sanofi Main Business
7.5.3 Sanofi COVID-19 Medicine Products, Services and Solutions
7.5.4 Sanofi COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi Recent Developments
7.6 Apotex
7.6.1 Apotex Profile
7.6.2 Apotex Main Business
7.6.3 Apotex COVID-19 Medicine Products, Services and Solutions
7.6.4 Apotex COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.6.5 Apotex Recent Developments
7.7 Bayer
7.7.1 Bayer Profile
7.7.2 Bayer Main Business
7.7.3 Bayer COVID-19 Medicine Products, Services and Solutions
7.7.4 Bayer COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.7.5 Bayer Recent Developments
7.8 Guangzhou Baiyunshan Guanghua Pharmaceutical
7.8.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Profile
7.8.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Main Business
7.8.3 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Products, Services and Solutions
7.8.4 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.8.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
7.9 Ipca Laboratories
7.9.1 Ipca Laboratories Profile
7.9.2 Ipca Laboratories Main Business
7.9.3 Ipca Laboratories COVID-19 Medicine Products, Services and Solutions
7.9.4 Ipca Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.9.5 Ipca Laboratories Recent Developments
7.10 Sichuan Sunny Hope
7.10.1 Sichuan Sunny Hope Profile
7.10.2 Sichuan Sunny Hope Main Business
7.10.3 Sichuan Sunny Hope COVID-19 Medicine Products, Services and Solutions
7.10.4 Sichuan Sunny Hope COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.10.5 Sichuan Sunny Hope Recent Developments
7.11 Zydus Cadila
7.11.1 Zydus Cadila Profile
7.11.2 Zydus Cadila Main Business
7.11.3 Zydus Cadila COVID-19 Medicine Products, Services and Solutions
7.11.4 Zydus Cadila COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.11.5 Zydus Cadila Recent Developments
7.12 Teva
7.12.1 Teva Profile
7.12.2 Teva Main Business
7.12.3 Teva COVID-19 Medicine Products, Services and Solutions
7.12.4 Teva COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.12.5 Teva Recent Developments
7.13 Sun Pharma
7.13.1 Sun Pharma Profile
7.13.2 Sun Pharma Main Business
7.13.3 Sun Pharma COVID-19 Medicine Products, Services and Solutions
7.13.4 Sun Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.13.5 Sun Pharma Recent Developments
7.14 Rising Pharmaceutical
7.14.1 Rising Pharmaceutical Profile
7.14.2 Rising Pharmaceutical Main Business
7.14.3 Rising Pharmaceutical COVID-19 Medicine Products, Services and Solutions
7.14.4 Rising Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.14.5 Rising Pharmaceutical Recent Developments
7.15 KPC Group
7.15.1 KPC Group Profile
7.15.2 KPC Group Main Business
7.15.3 KPC Group COVID-19 Medicine Products, Services and Solutions
7.15.4 KPC Group COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.15.5 KPC Group Recent Developments
7.16 Bristol Laboratories
7.16.1 Bristol Laboratories Profile
7.16.2 Bristol Laboratories Main Business
7.16.3 Bristol Laboratories COVID-19 Medicine Products, Services and Solutions
7.16.4 Bristol Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.16.5 Bristol Laboratories Recent Developments
7.17 Shanghai Zhongxisanwei
7.17.1 Shanghai Zhongxisanwei Profile
7.17.2 Shanghai Zhongxisanwei Main Business
7.17.3 Shanghai Zhongxisanwei COVID-19 Medicine Products, Services and Solutions
7.17.4 Shanghai Zhongxisanwei COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.17.5 Shanghai Zhongxisanwei Recent Developments
7.18 Shanghai Pharma
7.18.1 Shanghai Pharma Profile
7.18.2 Shanghai Pharma Main Business
7.18.3 Shanghai Pharma COVID-19 Medicine Products, Services and Solutions
7.18.4 Shanghai Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.18.5 Shanghai Pharma Recent Developments
8 Industry Chain Analysis
8.1 COVID-19 Medicine Industrial Chain
8.2 COVID-19 Medicine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 COVID-19 Medicine Sales Model
8.5.2 Sales Channel
8.5.3 COVID-19 Medicine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

The global market for COVID-19 Medicine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for COVID-19 Medicine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for COVID-19 Medicine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for COVID-19 Medicine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of COVID-19 Medicine include Advanz Pharma, Kyung Poong, Mylan, Novartis, Sanofi, Apotex, Bayer, Guangzhou Baiyunshan Guanghua Pharmaceutical and Ipca Laboratories, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for COVID-19 Medicine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of COVID-19 Medicine by region & country, by Type, and by Application.
The COVID-19 Medicine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 Medicine.

Market Segmentation
By Company
Advanz Pharma
Kyung Poong
Mylan
Novartis
Sanofi
Apotex
Bayer
Guangzhou Baiyunshan Guanghua Pharmaceutical
Ipca Laboratories
Sichuan Sunny Hope
Zydus Cadila
Teva
Sun Pharma
Rising Pharmaceutical
KPC Group
Bristol Laboratories
Shanghai Zhongxisanwei
Shanghai Pharma
Segment by Type:
Tablet
Injection
Segment by Application
Patients With Mild Symptoms
Critically Ill
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of COVID-19 Medicine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of COVID-19 Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of COVID-19 Medicine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 COVID-19 Medicine Product Introduction
1.2 Global COVID-19 Medicine Market Size Forecast
1.3 COVID-19 Medicine Market Trends & Drivers
1.3.1 COVID-19 Medicine Industry Trends
1.3.2 COVID-19 Medicine Market Drivers & Opportunity
1.3.3 COVID-19 Medicine Market Challenges
1.3.4 COVID-19 Medicine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global COVID-19 Medicine Players Revenue Ranking (2023)
2.2 Global COVID-19 Medicine Revenue by Company (2019-2024)
2.3 Key Companies COVID-19 Medicine Manufacturing Base Distribution and Headquarters
2.4 Key Companies COVID-19 Medicine Product Offered
2.5 Key Companies Time to Begin Mass Production of COVID-19 Medicine
2.6 COVID-19 Medicine Market Competitive Analysis
2.6.1 COVID-19 Medicine Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by COVID-19 Medicine Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Medicine as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tablet
3.1.2 Injection
3.2 Global COVID-19 Medicine Sales Value by Type
3.2.1 Global COVID-19 Medicine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global COVID-19 Medicine Sales Value, by Type (2019-2030)
3.2.3 Global COVID-19 Medicine Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Patients With Mild Symptoms
4.1.2 Critically Ill
4.1.3 Other
4.2 Global COVID-19 Medicine Sales Value by Application
4.2.1 Global COVID-19 Medicine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global COVID-19 Medicine Sales Value, by Application (2019-2030)
4.2.3 Global COVID-19 Medicine Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global COVID-19 Medicine Sales Value by Region
5.1.1 Global COVID-19 Medicine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global COVID-19 Medicine Sales Value by Region (2019-2024)
5.1.3 Global COVID-19 Medicine Sales Value by Region (2025-2030)
5.1.4 Global COVID-19 Medicine Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America COVID-19 Medicine Sales Value, 2019-2030
5.2.2 North America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe COVID-19 Medicine Sales Value, 2019-2030
5.3.2 Europe COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific COVID-19 Medicine Sales Value, 2019-2030
5.4.2 Asia Pacific COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America COVID-19 Medicine Sales Value, 2019-2030
5.5.2 South America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa COVID-19 Medicine Sales Value, 2019-2030
5.6.2 Middle East & Africa COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions COVID-19 Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions COVID-19 Medicine Sales Value
6.3 United States
6.3.1 United States COVID-19 Medicine Sales Value, 2019-2030
6.3.2 United States COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe COVID-19 Medicine Sales Value, 2019-2030
6.4.2 Europe COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China COVID-19 Medicine Sales Value, 2019-2030
6.5.2 China COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.5.3 China COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan COVID-19 Medicine Sales Value, 2019-2030
6.6.2 Japan COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea COVID-19 Medicine Sales Value, 2019-2030
6.7.2 South Korea COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia COVID-19 Medicine Sales Value, 2019-2030
6.8.2 Southeast Asia COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India COVID-19 Medicine Sales Value, 2019-2030
6.9.2 India COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.9.3 India COVID-19 Medicine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Advanz Pharma
7.1.1 Advanz Pharma Profile
7.1.2 Advanz Pharma Main Business
7.1.3 Advanz Pharma COVID-19 Medicine Products, Services and Solutions
7.1.4 Advanz Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.1.5 Advanz Pharma Recent Developments
7.2 Kyung Poong
7.2.1 Kyung Poong Profile
7.2.2 Kyung Poong Main Business
7.2.3 Kyung Poong COVID-19 Medicine Products, Services and Solutions
7.2.4 Kyung Poong COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.2.5 Kyung Poong Recent Developments
7.3 Mylan
7.3.1 Mylan Profile
7.3.2 Mylan Main Business
7.3.3 Mylan COVID-19 Medicine Products, Services and Solutions
7.3.4 Mylan COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.3.5 Novartis Recent Developments
7.4 Novartis
7.4.1 Novartis Profile
7.4.2 Novartis Main Business
7.4.3 Novartis COVID-19 Medicine Products, Services and Solutions
7.4.4 Novartis COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.4.5 Novartis Recent Developments
7.5 Sanofi
7.5.1 Sanofi Profile
7.5.2 Sanofi Main Business
7.5.3 Sanofi COVID-19 Medicine Products, Services and Solutions
7.5.4 Sanofi COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi Recent Developments
7.6 Apotex
7.6.1 Apotex Profile
7.6.2 Apotex Main Business
7.6.3 Apotex COVID-19 Medicine Products, Services and Solutions
7.6.4 Apotex COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.6.5 Apotex Recent Developments
7.7 Bayer
7.7.1 Bayer Profile
7.7.2 Bayer Main Business
7.7.3 Bayer COVID-19 Medicine Products, Services and Solutions
7.7.4 Bayer COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.7.5 Bayer Recent Developments
7.8 Guangzhou Baiyunshan Guanghua Pharmaceutical
7.8.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Profile
7.8.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Main Business
7.8.3 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Products, Services and Solutions
7.8.4 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.8.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
7.9 Ipca Laboratories
7.9.1 Ipca Laboratories Profile
7.9.2 Ipca Laboratories Main Business
7.9.3 Ipca Laboratories COVID-19 Medicine Products, Services and Solutions
7.9.4 Ipca Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.9.5 Ipca Laboratories Recent Developments
7.10 Sichuan Sunny Hope
7.10.1 Sichuan Sunny Hope Profile
7.10.2 Sichuan Sunny Hope Main Business
7.10.3 Sichuan Sunny Hope COVID-19 Medicine Products, Services and Solutions
7.10.4 Sichuan Sunny Hope COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.10.5 Sichuan Sunny Hope Recent Developments
7.11 Zydus Cadila
7.11.1 Zydus Cadila Profile
7.11.2 Zydus Cadila Main Business
7.11.3 Zydus Cadila COVID-19 Medicine Products, Services and Solutions
7.11.4 Zydus Cadila COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.11.5 Zydus Cadila Recent Developments
7.12 Teva
7.12.1 Teva Profile
7.12.2 Teva Main Business
7.12.3 Teva COVID-19 Medicine Products, Services and Solutions
7.12.4 Teva COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.12.5 Teva Recent Developments
7.13 Sun Pharma
7.13.1 Sun Pharma Profile
7.13.2 Sun Pharma Main Business
7.13.3 Sun Pharma COVID-19 Medicine Products, Services and Solutions
7.13.4 Sun Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.13.5 Sun Pharma Recent Developments
7.14 Rising Pharmaceutical
7.14.1 Rising Pharmaceutical Profile
7.14.2 Rising Pharmaceutical Main Business
7.14.3 Rising Pharmaceutical COVID-19 Medicine Products, Services and Solutions
7.14.4 Rising Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.14.5 Rising Pharmaceutical Recent Developments
7.15 KPC Group
7.15.1 KPC Group Profile
7.15.2 KPC Group Main Business
7.15.3 KPC Group COVID-19 Medicine Products, Services and Solutions
7.15.4 KPC Group COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.15.5 KPC Group Recent Developments
7.16 Bristol Laboratories
7.16.1 Bristol Laboratories Profile
7.16.2 Bristol Laboratories Main Business
7.16.3 Bristol Laboratories COVID-19 Medicine Products, Services and Solutions
7.16.4 Bristol Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.16.5 Bristol Laboratories Recent Developments
7.17 Shanghai Zhongxisanwei
7.17.1 Shanghai Zhongxisanwei Profile
7.17.2 Shanghai Zhongxisanwei Main Business
7.17.3 Shanghai Zhongxisanwei COVID-19 Medicine Products, Services and Solutions
7.17.4 Shanghai Zhongxisanwei COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.17.5 Shanghai Zhongxisanwei Recent Developments
7.18 Shanghai Pharma
7.18.1 Shanghai Pharma Profile
7.18.2 Shanghai Pharma Main Business
7.18.3 Shanghai Pharma COVID-19 Medicine Products, Services and Solutions
7.18.4 Shanghai Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.18.5 Shanghai Pharma Recent Developments
8 Industry Chain Analysis
8.1 COVID-19 Medicine Industrial Chain
8.2 COVID-19 Medicine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 COVID-19 Medicine Sales Model
8.5.2 Sales Channel
8.5.3 COVID-19 Medicine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(通信・IT)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る